Industry news that matters to you.  Learn more

Archives for April 2011

Aushon Launches New SignaturePLUS System for Multiplex Protein Biomarker Analysis

Aushon announced today the global launch of its next generation SignaturePLUS Imaging and Analysis System. The SignaturePLUS system is designed to meet the cost and performance needs of researchers for accurate, reproducible, and reliable multiplex protein biomarker analysis across pre-clinical, clinical and diagnostics applications in all therapeutic areas.

BG Medicine, Boston Scientific Collaborate to Study Biomarkers Relevant to Congestive Heart Failure and Cardiac-Resynchronization Therapy

BG Medicine, Inc. announced last week that it has entered into a research collaboration agreement with Boston Scientific Corporation, a leading medical device manufacturer, to study the role of galectin-3 as an aid in patient screening for cardiac-resynchronization therapy (CRT) using patient data from the MADIT-CRT study. The collaboration is designed to focus on better understanding the important MADIT-CRT patient population and whether galectin-3 can help identify patients who would derive the most benefit from CRT. This collaboration also involves using BG Medicine’s biomarker discovery capabilities to identify other biomarkers that correlate to CRT treatment response.

Endothelial Microparticles (EMPs) in the Blood Useful for Identifying Early Signs of Emphysema

According to a recent study published in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine, small particles in the blood released by cells lining the lungs may help clinicians diagnose emphysema in its earliest stages. The particles, called endothelial microparticles (EMPs), are shed during disease progression as pulmonary capillaries in the lungs are injured and die.

Five Metabolite Levels May Improve Risk Prediction for Diabetes

Researchers at Massachusetts General Hospital (MGH) recently identified five amino acids whose levels indicated an increased diabetes risk in a general population. Moreover, the biomarkers could differentiate, among individuals with traditional risk factors such as obesity, those most likely to actually develop diabetes. The findings are published in the journal Nature Medicine.